Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05 2022 - 7:30AM
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced that it will host a conference call and webcast to review
updated interim results of its Phase 1 HPN217 clinical program
presented at the 64th American Society of Hematology (ASH) Annual
Meeting and provide a corporate update.
The live call/webcast will take place at 4:30 p.m. ET / 3:30
p.m. CT / 1:30 p.m. PT on December 12, 2022 and can be accessed by
dialing 1-877-407-9039 for domestic callers and 1-201-689-8470 for
international callers with conference ID code number 13734677. A
webcast of the live call will be available online in the investor
relations section of the Harpoon website at www.harpoontx.com. A
replay of the webcast will be available shortly after the live
event and can be accessed at the same weblink.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel TriTACs
initially focused on the treatment of solid tumors and hematologic
malignancies. Harpoon has also developed a proprietary ProTriTAC™
platform, which applies a prodrug concept to its TriTAC platform to
create a therapeutic T cell engager that remains inactive until it
reaches the tumor. Harpoon’s third proprietary technology platform,
extended release TriTAC-XR, is designed to mitigate cytokine
release syndrome. For additional information about Harpoon
Therapeutics, please visit www.harpoontx.com.
Contacts:
ICR Westwicke:Robert H. UhlManaging
Director858-356-5932robert.uhl@westwicke.com
Media:uncapped
Communications512-825-2603monique.greer@uncappedcommunications.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2023 to Apr 2024